drugset / Trial / NCT01199640
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
RandomizedSingle-groupSingle-blindTreatment
Summary
This was a phase 2a study of MLN1202 to determine safety, tolerability and initial efficacy in patients with relapsing-remitting multiple sclerosis (RRMS). It was conducted in 2 dose cohorts enrolling a total of 50 patients. Efficacy was assessed by comparing the numbers of new gadolinium-enhancing brain lesions during the screening and treatment periods.
Timeline
- Start
- 2005-05
- Primary completion
- 2007-07
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PLOZALIZUMAB | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | PLOZALIZUMAB | Monoclonal antibody | 8 mg/kg | Intravenous |